Partnerships and Patient-Centric Innovation: Shaping India's Next Pharma Growth Chapter

Deepak Arora, Country Lead and Managing Director & General Manager, Sanofi India Limited

 Partnerships and Patient-Centric Innovation: Shaping India's Next Pharma Growth Chapter, Deepak Arora, India Pharma Outlook

The pharmaceutical industry is undergoing a significant transformation, moving beyond its traditional strengths in manufacturing and generics towards innovation, research and patient-centric healthcare.

As India strengthens its position in the global pharmaceutical landscape, collaboration between industry, government, academia and healthcare stakeholders will play an increasingly important role in driving this transition.

On the topic of the power of partnerships in advancing healthcare innovation and strengthening India's pharmaceutical ecosystem, Deepak Arora, Country Lead and Managing Director & General Manager – Pharma at Sanofi India Limited, shares his perspectives on patient-centric leadership, India's evolving innovation capabilities, public-private collaboration and the policy reforms needed to encourage research and development. Drawing on more than three decades of experience across international markets, he also highlights how collective action can improve healthcare access and address public health challenges.

With more than three decades of experience in the pharmaceutical industry across different markets and geographies, what is one lesson from your experience that has always stayed with you?

Irrespective of geographical boundaries, the organizations we work for, or the teams we lead, one fundamental principle remains unchanged: keeping the patient at the center. The strategy should follow from that principle.

I often tell my team that whenever they make an important decision, they should imagine an empty chair with a patient sitting in it. Every decision should be made with the responsibility of serving that patient in mind.

Similarly, trust is another important element. Transparency, consistency in communication, and delivering on commitments are essential, particularly in an environment filled with uncertainty. Connecting to that, leadership itself is also about enabling teams to serve the larger purpose of putting patients first.

Do the fundamentals of solving challenges differ across cultures, or do they remain the same at the core?

What binds us together in this industry is the patient. What may change are the ecosystem and the readiness of the country in which we serve that patient.

For example, in Africa, the complete healthcare ecosystem needs to be developed before innovation can be introduced effectively. Bringing innovation into a country does not achieve much if diagnostic screening and reimbursement systems are not ready. Public-private partnerships also play an important role in building this ecosystem.

India, on the other hand, already has experience with innovation and a certain level of readiness for access. So, the requirement here is to expand it.

The challenges are different because the public and private healthcare ecosystems operate differently. While a large number of patients and much of the volume are in the public sector, whereas the private sector largely depends on out-of-pocket expenditure.

Therefore, the approach may differ depending on the country, but the patient remains the central consideration.

According to you what has been the biggest transformation in India's pharmaceutical industry over the last six decades?

India has traditionally been known as the pharmacy of the world, with its strength in manufacturing and generics. However, the industry is now moving towards writing its next chapter in innovation.

Some of the developments I have witnessed include the growth of Global Capability Centers (GCCs), greater attention to early innovation, and constructive engagement with the government to discuss reforms and policies that can strengthen the innovation ecosystem.

Having returned after four years, the transformation is particularly evident. India is no longer being recognized only as a manufacturing and generic powerhouse rather it is emerging as a country that can contribute to global innovation.

And proving this two major developments stand out. The first is BioPharma Shakti and the reforms being introduced by the government. The second is the Indo-French Innovation Year and the Bharat Innovates initiative, which brought deep-tech and AI startups from India onto a global platform and helped present India's innovation capabilities to the world.

Understanding the importance of partnerships, how does the idea of power of partnership resonate with you?

We experience the power of partnerships every day. Public-private partnerships with the government and stakeholders, including patient advocacy groups, are essential. Improving patients' quality of life cannot be achieved by one organization working alone. It requires different stakeholders to work together, communicate the same message, and ensure that it reaches the people who need it.

It is also not a question of innovation versus generic organizations. As a company, we work with the Indian pharmaceutical industry to take our innovations to the last mile. We have been working with organizations such as Emcure, Cipla, and DRL. This is another example of how partnerships can help extend access.

The growth of Make in India initiatives and GCC forums, through which innovation hubs are being developed, is also evidence of partnerships between the industry and the government, including state governments.

What role did Sanofi play in India's polio eradication campaign, and what lessons did it leave behind?

Polio eradication was not just a campaign. It was an ambitious goal that was taken up as a challenge and made achievable through collective efforts. Active partnerships played a major role in bringing together the pharmaceutical industry, public health organizations, patient advocacy groups, and supply-chain stakeholders around a shared mission.

Sanofi focused on ensuring consistent vaccine supply, reaching the last mile, and creating awareness. It was not simply about pushing the campaign from one end. Efforts had to come from both sides to ensure that the vaccines reached people and that the initiative was supported.

This achievement cannot be attributed to one organization alone. It was the collective achievement of all stakeholders. The biggest lesson is that we cannot accomplish such goals independently. We have to work together and sometimes take the challenge personally to make it happen. I am proud to have been part of an organization that contributed to India's polio eradication mission.

Can the polio eradication campaign serve as a blueprint for addressing future public health challenges?

COVID-19 provided another example of how industries can come together. It did not matter where the innovation originated; technology transfers took place, and stakeholders worked collectively to address the challenge of vaccine availability. The effort was not limited to making vaccines available in India. It also involved ensuring that they reached people in the last mile and supporting the rest of the world.

The polio-free India campaign and the COVID-19 response have given us a clear blueprint. Different therapeutic areas and diseases will bring their own challenges, but the experience has shown that we are capable of working together.

We should not duplicate efforts; instead, we should replicate successful approaches and bridge the gaps where we could not perform well earlier. We should also focus on speed over perfection to make things happen faster.

What are the biggest opportunities for India as it emerges as a global hub for innovation?

I would bring the discussion back to GCCs. I do not particularly like the term Global Capability Centers because it can create the impression that these centers are meant only for backend work or cost reduction. Today, I would rather call them innovation hubs.

Sanofi is one example. Over the last three years, we have expanded our resources, and our workforce is moving towards 5,000 employees across two offices in Hyderabad. The work being undertaken here is no longer limited to conventional go-to-market strategies.

We are working in areas such as artificial intelligence, data science, early research and development, health economics and outcomes research, and innovative access models for different countries. These activities are being driven by India's talent.

Make in India should not be understood only in terms of manufacturing facilities. It is also about creating innovation hubs and developing talent through GCCs for the rest of the world. This transformation is already happening, and I believe that within the next two to three years, we will see more innovation coming from India.

Our responsibility is not only to bring Indian innovation to the global stage but also to identify opportunities to apply some of these innovations within our own country.

What capabilities should India invest in as GCCs and innovation take center stage?

Some of the important areas of investment include artificial intelligence, big data science, real-world evidence, and health economics and outcomes research. India was somewhat behind in health economics and outcomes research, but we are now catching up.

Innovation should not be viewed only in terms of price. It should also be assessed through cost-effectiveness. The capabilities we are developing can help us demonstrate this and apply some of these approaches in the public healthcare sector.

Building capabilities in health economics and real-world evidence, along with generating our own data, can change the perception that innovation is expensive. It can help demonstrate how innovation can also be cost-effective.

How can industry-government collaboration and public policy support innovation in India?

One important requirement is to encourage investment in India so that the country is not viewed only as a manufacturing destination. Manufacturing and generics should coexist with innovation. This can happen when the industry receives incentives for research and development and when reforms are introduced in areas such as intellectual property.

Regulatory Data Protection (RDP) is one example. There are several misconceptions surrounding it, but countries such as China have taken steps to protect technical data. Significant investment goes into generating this data in terms of money, effort, resources, and time. If there is uncertainty about whether the data will be protected or appropriately incentivized, it becomes difficult to encourage further investment.

India therefore needs forward-looking policies that protect data, strengthen regulatory pathways, improve ease of doing business, and enable innovation to reach the market earlier.

I would also like to clarify that RDP does not mean extending patents. It is about protecting clinical data, which can help innovation and generics coexist, while supporting affordability and access.

What message would you give to the next generation entering the pharmaceutical industry?

This takes me back to why I joined the pharmaceutical industry three decades ago. I had never planned to enter this field. However, one presentation changed my perspective. A general manager at Eli showed us a product, and it reminded me of something I had seen at home. My mother was taking insulin, and I understood that there was no life without it.

That is the connection I want young professionals to develop with the pharmaceutical industry. It is not just about product launches, brands, money, or assets. The biggest asset of any organization is its people, and people should join with a sense of purpose.

The purpose is to serve millions of people living with diseases and improve their lives. Regardless of the function they work in, professionals should remember that their work contributes to bringing a smile to patients and improving the lives of people suffering from serious diseases. We should also remember that any one of us could become a patient tomorrow.

The speed of translating innovation into execution remains important. Today's talent is also ahead in the way it thinks about technology. Artificial intelligence is already familiar to the younger generation, and they approach it from a different perspective. Combining that outlook with patient-centricity will be important for the industry's future. I welcome young people to join the pharmaceutical industry.

on the deck

Most Viewed

Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts Fostering a Quality Culture in the Pharmaceutical Industry Advancements in Computer-Aided Drug Design for Pharmaceutical Research Why India is Gaining Popularity for Clinical Trials The Future of Kidney Transplants in India Usage of Conversational AI in the Health Insurance Sector Strategies for India to Reduce Its API Dependence on China Business Impact of USFDA Approvals on Indian Pharma Companies Innovative Strategies for Expanding Access to Life Saving Healthcare Solutions Badhal Village Crisis: How Rapid Diagnostics Could Have Saved Lives Why India is a Hotspot for Biotech Startups? Why Adapting Flexibility in IP Rights will Drive Generics Market Meeting the Challenges of High-Potency API (HPAPI) Production Impact of Human Factors Engineering on Medical Device Safety The Future of Pharma: Embracing Continuous Manufacturing The Role of Orphan Drugs in Treating Rare Diseases Emerging Technologies Shaping the Future of Drug Formulation Strategies for Optimizing Pharmaceutical Supply Chain Efficiency The Future of Medicine: Harnessing the Power of RNA-based Therapeutics AI in Medicine: Unmasking the Myths and Embracing the Transformative Reality Cycle Pharma Acquires Banner Life Sciences WHO's First-ever Global Summit on Traditional Medicine Starts in Gujarat The Importance of Data Integrity in Pharmaceutical Quality Control DCGI in Talks with Stakeholders to Develop a Standardised Web Platform to Assure Drug Quality and Patient Safety Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment Streamlining Laboratory Operations with a Modern LIMS Healthtech Start-up Suraksha QR Ropes In Actor Murali Sharma as its Brand Ambassador Unlocking the Potential of Pharmacogenomics: Enhancing Drug Safety and Efficacy The Impact of Pharmaceutical Testing on Drug Development India has Identified Three Health Priorities to Strengthen Global Health Infrastructure, says WHO National Health Authority launches 100 Microsites Project to Speed Up Digital Health Adoption India Should Partner with Australia to avail PBS for the Selection, Listing, and Pricing processes of exported drugs, says Sudarshan Jain Zydus Lifesciences India More than Doubles Profit Due to Increased Sales in the US India Triples Organ Donations over Past Decade says Union health minister Mansukh Mandaviya Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy Three Pharma Marketing Strategies That Drive Sales Novartis Targets India's Rare Disease Market with 17 Clinical Programs UK Health Regulator approves GSK's Vaccine for the common respiratory virus RSV WHO Urges Increased Use Of Recommended Malaria-Fighting Tools Karnataka Budget Offered a Significant Boost to Health & Lifesciences Start-ups with Focus on Infrastructure & Innovation Three High Potential Moonshot Project Areas in Pharma CCI approves Bharat Biotech International-Eastman Exports deal How Biotech is Revolutionizing the Fight Against Cancer LifeCell and HaystackAnalytics ink strategic pact to scale-up TB whole genome sequencing pan-India Mankind Pharma IPO To Open On April 25 With A Price Fixed At Rs 1,026-1,080 Per Share US CDC Approves Second Omicron-Updated COVID Booster For Adults Three Trends that will Impact Pharmaceutical Industry in 2023 ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck Designing Impactful Leadership and Talent Management Programs with Strategies for Success Novo Nordisk and Valo Health Partner to develop novel Treatments FOPE Calls for Extended Deadline for Schedule M Compliance Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation Roche Secures US FDA Approval for its Ultra-Sensitive ISH test Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A Taro Pharma To Acquire entire stake in Antibe Therapeutics Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 Emcure Pharma Launches Largest R&D Centre in Ahmedabad Zydus Bags USFDA Nod for Phase II(b) Trial to Optimize Usnoflast Dosage US FDA Approves Amgen's Lumakras-Vectibix Combo for KRAS G12C-Mutated mCRC Glenmark Pharma Unveils generic anticoagulant injectable emulsion Strides Pharma Bags USFDA Nod for OTC Acetaminophen-Ibuprofen Combo Tablets US FDA Lifts Hold on Sanofi's Trial to Make Cialis Available Over-the-Counter Hoth Therapeutics Expands Intellectual Property with New Patents Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID Pharma and Healthcare Sector Eyes Union Budget 2025 for Innovation Boost How Innovative Drug Formulations are Enhancing Treatment Outcomes Apollo and Mayapada Healthcare Unite to Boost Indonesia's Healthcare Novo Nordisk Reports Positive Phase 1b/2a Results for Amycretin Govt to Extend Schedule M Compliance Deadline for Drug Manufacturers to Dec Lupin Secures US FDA Nod for Ipratropium Bromide Nasal Solution ANDA Granules Pharmaceuticals Secures USFDA Nod for Key Generic Drug Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation Pharma Testing Market Surges with Rising Demand for Biologics ISTH Releases Clinical Practice Guideline For Haemophilia Treatment Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug Takeda and Ascentage Pharma Ink Option Agreement For Olverembatinib Enhancing Compliance through Effective Pharmaceutical Regulatory Affairs Strategies India poised to become a Global Hub for Clinical Trials: Exec SCHOTT Pharma Unveils Next-Gen Polymer Syringes for Enhanced Safety GSK's Jemperli Gains EU Nod for First-Line Treatment of Endometrial Cancer Union Health Secretary Urges Stronger Drug Regulations for Quality Control Telangana Govt Inks Landmark Deals to Propel Life Sciences and Job Growth R&D in Indian Pharma: Breakthroughs and Innovations in 2024 Dr. Reddy's Partners with Shanghai Henlius to Develop Cancer Drug Uniphar Expands Global Footprint with Three New Facilities 74th Indian Pharmaceutical Congress 2025 Opens Registrations AGC Pharma Expands HPAPI Capabilities in Barcelona to Meet Growing Demand The Future of Genomic Sequencing: Trends That Will Define the Next Decade Lexaria Bioscience Ethics Review Board Nod to Commence New GLP-1 Study Amitabh Kant Urges India to Focus on Innovation at BioAsia 2025 Government Enhances Research & Integration Initiatives in Unani Medicine Blind & Deaf individuals face Major Barriers to access Medicines: Report C-CAMP and PariSante Campus launched Indo-French Life Sciences Hub Jaguar Health Begins Pediatric Trial for Crofelemer in Short Bowel Syndrome Algiax Pharma Reports Promising Phase 2a Results for AP-325 Govt Bans 34 Antimicrobials for Use in Animals Pharmaceutical Procurement Strategies: How to Optimize Costs Personalized Medicine: Get Tailored Treatment Plans for You Now How to Bridge the Healthcare Gap in Emerging Markets with MedTech The Evolution of In-Vitro Diagnostics: Trends and Future Prospects Needle-Free Injection System: A Game Changer in Less Pain Vaccination How Global Capability Centers are Shaping the Future of Biometrics Building a Successful Pharma Brand in India: The Role of Scientific Communication Unlocking India's Innovation Potential in Pharma The Future of Green Chemistry in API Production Top 10 Pharmaceutical Recruitment Consultants - 2024 | Pharma Outlook Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond Mass Spectrometry in Biomarker Discovery for Early Disease Detection Iconovo and Lonza Team up to Advance Intranasal Biologic with ICOone Nasal Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound Balancing Innovation and Affordability in Medical Solutions for India Changing Landscape for LTBI and Syndromic Testing Methodologies How Advanced Training Methods can Enhance Patient Care Balancing Cost Efficiency and Compliance in Pharmaceutical Manufacturing LUB Urges Govt to Scrap Mandatory Lab Testing for Cough Syrup Exports Role of Optical Imaging in Early Cancer Detection and Treatment Hoth Therapeutics Unveils Promising Data for KIT-Targeting Therapy Pharmexcil Engages ASEAN Nations to Boost Pharma Trade Ties Fortis Partners with Teleflex for South Asia UroLift Training Anti-Infectives: How New Research is Shaping Infection Control Building Bridges for Sustainable Growth through Strategic Alliances in Ethical Pharmaceuticals Quality as the Cornerstone of Lab Solutions FDA Approves Roch's NSCLC Diagnostic Linked to Emrelis How Early Detection is Transforming Cancer Treatment in India Ensuring Data Privacy in Pharma World Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings How Organic Synthesis is Accelerating Drug Discovery in Pharma Strategic finance for pharmaceutical innovation and stability Top 10 Teleradiology Service Providers - 2024 | Pharma Outlook Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care Top 10 In Vitro Diagnostics Companies - 2024 | Pharma Outlook Phytopharmaceuticals: Driving Global Herbal Medicine Innovation Gender Gap in Healthcare: Why Women's Health Needs More Research Impact of Modern Technology on the Indian Life Sciences Sector Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections The Role of Customizable Stent Grafts for Treating Complex Anatomies Nutraceuticals vs Pharmaceuticals: Complementary or Alternative in Chronic Disease Management? Top 10 Pharma CDMO Companies In India – 2023 | Pharma Outlook Leaping Towards Global Compliance with Revised Schedule M Meril Concludes TechVentory, Boosts AI-Driven Healthcare Supply Chains 10 Pharma Sector Revolutions in India Standardizing Medicine Labeling and Embracing Digital Transformation Creating a patient-centric healthcare ecosystem for all Biomanufacturing of Enzymes: A Sustainable Approach to Industrial Biotechnology Integrating CSR into HR Practices to Enhance Brand Reputation in Pharma Merck Launches Phase 3 Trial for Promising Dengue Vaccine V181 Breakthrough: Eye-Opening Healthcare Strategies Doctors Swear By on Doctor's Day 2025 Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail Alcon Launches Innovative Daily Lenses Designed for Long-lasting Comfort Apisolex Excipient by Lubrizol Backs Phase I Drug Success FDA Approves Enflonsia to Prevent RSV in Infants with One Dose Biosimilars in India 2025 Market Trends, Growth Forecast & Opportunities How Regulations Are Shaping India's Medical Device Landscape Bharat Biotech Partners with GSK for Shigella Vaccine Development Eli Lilly Obesity Drug Shows 11.5% Weight Loss in 12 Weeks Laborate Pharmaceuticals: Illuminating Pathways Of Quality, Affordability Innovation In Healthcare Sun Pharma Bags CDSCO Approval to Produce Fexuprazan Hydrochloride Tablets The Fusion of Biology, Medicine, Health, and AI Glenmark Gets DCGI Nod to Launch Oncology Drug BRUKINSA in India Kyndryl Partners with Dr Reddys to Automate Global IT Operations How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants Top 10 Women Disruptors in Asia Pharmaceutical Industry

Editor's Guest

Related Articles

© 2026 India Pharma Outlook. All Rights Reserved.